Literature DB >> 26306069

Does Profile of Hemoglobin Eβ-thalassemia Patients Change After Splenectomy? Experience of a Tertiary Thalassemia Care Centre in Eastern India.

Prakas Kumar Mandal1, Malay Kumar Ghosh2, Maitreyee Bhattacharyya2.   

Abstract

Hemoglobin Eβ-thalassemia is by far the commonest form of thalassemia intermedia. Its phenotype ranges from mild anemia to severe transfusion-dependency necessitating splenectomy in many patients. The present study aimed to systematically analyze both clinical as well as laboratory parameters in profile of Eβ-thalassemia patients after splenectomy in terms of transfusion requirement, infections and other complications. Retrospective study conducted over a period of 3 years included 72 cases of splenectomized Eβ-thalassaemia patients, considering decrease in transfusion requirements, new complications, antibiotic, anti-malarial prophylaxis and iron chelation therapy. Out of 1380 registered Eβ-thalassemia patients, 618 (44.78 %) were regularly transfused and 72(5.22 %) underwent splenectomy. Mean age of diagnosis was 10.3 years. Nineteen patients (26.4 %) underwent splenectomy between 5 and 10 years, 38 cases (52.7 %) between 10 and 20 years. The leading cause (51.39 %) for splenectomy was mechanical discomfort. Mean steady state hemoglobin raised from pre-splenectomy level of 5.43-6.8 gm/dl after splenectomy. Mean transfusion requirement reduced from 18.1 to 7.8 units/year. Mean serum ferritin level increased from 907.58 to 1,091.6 ng/ml. Post-splenectomy; 21 (29.17 %) patients developed facial deformities, 17 (23.6 %) delayed pubertal growth, 11 (15.28 %) venous thromboembolism, five (6.94 %) pulmonary hypertension and four (5.5 %) had extramedullary hematopoiesis. Five (6.96 %) patients had documented bacterial infections and two (2.78 %) suffered from malaria. Forty eight patients (66.67 %) started with iron chelation therapy; but majority (52.7 %) stopped. Major advantage of splenectomy is reduced transfusion requirement, though it cannot prevent skeletal abnormalities and delayed pubertal growth. In resource constraint countries like India, routine anti-malarial and antibacterial prophylaxis is not desirable; iron chelation therapy should be encouraged and ensured.

Entities:  

Keywords:  Hb Eβ-thalassemia; Iron chelation therapy; Post-splenectomy complications

Year:  2015        PMID: 26306069      PMCID: PMC4542765          DOI: 10.1007/s12288-014-0498-6

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  21 in total

1.  Hemoglobin E disorders in the north east India.

Authors:  S Piplani
Journal:  J Assoc Physicians India       Date:  2000-11

Review 2.  Studies in haemoglobin E beta-thalassaemia.

Authors:  Nancy F Olivieri; Giulia M Muraca; Angela O'Donnell; Anuja Premawardhena; Christopher Fisher; David J Weatherall
Journal:  Br J Haematol       Date:  2008-05       Impact factor: 6.998

3.  Hemoglobin E/beta thalassemia: the Canadian experience.

Authors:  M Fouladi; M L Macmillan; E Nisbet-Brown; N Klein; J Barlas; J S Waye; N F Olivieri
Journal:  Ann N Y Acad Sci       Date:  1998-06-30       Impact factor: 5.691

Review 4.  Optimal management of β thalassaemia intermedia.

Authors:  Ali T Taher; Khaled M Musallam; Maria Domenica Cappellini; David J Weatherall
Journal:  Br J Haematol       Date:  2011-01-20       Impact factor: 6.998

Review 5.  Thalassemia intermedia: revisited.

Authors:  Ali Taher; Hussain Isma'eel; Maria D Cappellini
Journal:  Blood Cells Mol Dis       Date:  2006-06-05       Impact factor: 3.039

6.  Variable clinical severity of Hb E beta-thalassemia among Indians.

Authors:  A Nadkarni; K Ghosh; A Gorakshakar; R Colah; D Mohanty
Journal:  J Assoc Physicians India       Date:  1999-10

7.  Iron overload and iron-chelating therapy in hemoglobin E-beta thalassemia.

Authors:  N F Olivieri; S De Silva; A Premawardena; S Sharma; A M Viens; C M Taylor; G M Brittenham; D J Weatherall
Journal:  J Pediatr Hematol Oncol       Date:  2000 Nov-Dec       Impact factor: 1.289

8.  Hemostatic alterations in splenectomized and non-splenectomized patients with beta-thalassemia/hemoglobin E disease.

Authors:  Amporn Tripatara; Arunee Jetsrisuparb; Jamaree Teeratakulpisarn; Kunnika Kuaha
Journal:  Thromb Res       Date:  2007-03-23       Impact factor: 3.944

Review 9.  Clinical and hematologic aspects of hemoglobin E beta-thalassemia.

Authors:  S Fucharoen; P Winichagoon
Journal:  Curr Opin Hematol       Date:  2000-03       Impact factor: 3.284

10.  Clinico-haematological profile of HbE syndrome in adults and children.

Authors:  S Tyagi; H P Pati; V P Choudhry; R Saxena
Journal:  Hematology       Date:  2004-02       Impact factor: 2.269

View more
  3 in total

1.  From the Editor-in-Chief's Desk.

Authors:  H P Pati
Journal:  Indian J Hematol Blood Transfus       Date:  2015-12       Impact factor: 0.900

Review 2.  Leg Ulcers: A Report in Patients with Hemoglobin E Beta Thalassemia and Review of the Literature in Severe Beta Thalassemia.

Authors:  Vikita Mehta; Abirami Kirubarajan; Amir Sabouhanian; Sanasi M Jayawardena; Priya Chandrakumaran; Nila Thangavelu; Refai Cader; Sachith Mettananda; Dayananda Bandara; Shawn Khan; David J Weatherall; Angela Allen; Anuja P Premawardhena; Nancy F Olivieri
Journal:  Acta Haematol       Date:  2021-11-09       Impact factor: 3.068

3.  Survival and complications in patients with haemoglobin E thalassaemia in Sri Lanka: a prospective, longitudinal cohort study.

Authors:  Anuja P Premawardhena; Dileepa Senajith Ediriweera; Amir Sabouhanian; Angela Allen; David Rees; Shanthimala de Silva; Windsor Perera; Nimal Katugaha; Mahinda Arambepola; Robert C Yamashita; Sachith Mettananda; Nilam Jiffry; Vikita Mehta; Refai Cader; Dayananda Bandara; Timothy St Pierre; Giulia Muraca; Christopher Fisher; Abirami Kirubarajan; Shawn Khan; Stephen Allen; Sanath P Lamabadusuriya; David J Weatherall; Nancy F Olivieri
Journal:  Lancet Glob Health       Date:  2021-11-26       Impact factor: 38.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.